Table 4. The relationship between copy number variations and prognosis of lung adenocarcinoma.
| Overall survivala (N = 313) | Progression free survivalb (N = 313) | |||
|---|---|---|---|---|
| Crude HR(95%CI) | Adjusted HRc(95%CI) | Crude HR(95%CI) | Adjusted HRc(95%CI) | |
| PBXIP1 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 0.62(0.43–0.91) | 0.58(0.39–0.86) | 0.80(0.58–1.11) | 0.81(0.58–1.13) |
| TERT | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 0.81(0.52–1.25) | 0.85(0.54–1.32) | 0.65(0.44–0.97) | 0.67(0.45–0.99) |
| CEP72 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 0.78(0.53–1.15) | 0.88(0.60–1.31) | 0.90(0.64–1.25) | 1.03(0.73–1.44) |
| BRD9 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 1.00(0.62–1.62) | 1.35(0.82–2.23) | 1.20(0.78–1.85) | 1.49(0.95–2.33) |
| TRIP13 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 0.87(0.55–1.38) | 1.09(0.68–1.74) | 0.99(0.65–1.49) | 1.19(0.78–1.81) |
| SLC9A3 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 1.12(0.66–1.91) | 1.07(0.63–1.83 | 0.88(0.59–1.33) | 0.84(0.55–1.27) |
| SDHA | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 1.15(0.78–1.69) | 1.18(0.79–1.75) | 0.99(0.71–1.36) | 0.95(0.68–1.32) |
| SLC6A19 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 0.83(0.55–1.25) | 0.93(0.61–1.42) | 0.95(0.66–1.37) | 0.99(0.69–1.44) |
| PDCD6 | ||||
| amplification | 1.00 | 1.00 | 1.00 | 1.00 |
| nonamplification | 1.13(0.77–1.66) | 1.14(0.77–1.68) | 0.83(0.60–1.15) | 0.82(0.59–1.15) |
a
Overall survival was calculated by subtracting the date when the patient was first treated from the date of death, and patients were censored when lost of follow-up.
b
Progression free survival was calculated by subtracting the date of first treatment from the date of recurrence of, metastasis of or death from lung adenocarcinoma.
c
Adjustment: age, gender, smoking status and TNM stage.